Our research program leverages new cell engineering technologies and pre-clinical trials in genetically engineered mice for advancing the conceptual understanding of the tumor microenvironment. These research efforts are poised to identify new mechanisms and vulnerabilities in the tumor microenvironment that may be harnessed for improving the efficacy and broadening the applicability of immune therapies. Key approaches focus on reprogramming the immunosuppressive and pro-angiogenic tumor microenvironment, which is pursued in mouse cancer models that are stratified according to clinical parameters and through genetic refinement. Our research program also envisions relaunching the clinical applicability of dendritic cell vaccines through an innovative biotechnological platform.